Targeting the Non-Homologous End Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin by Enhancing p53-Mediated Senescence

Journal:
Cancer Research
Published:
DOI:
10.1158/0008-5472.can-25-1858
Affiliations:
6
Authors:
11
Go to article
Institutions Authors Share
Netherlands Cancer Institute (NKI), Netherlands
6.833333
 0.62
Oncode Institute, Netherlands
3.833333
 0.35
VU Amsterdam, Netherlands
0.333333
 0.03